BRCA1 and neoplasm: An early-phase trial assessing the BET inhibitor ZEN-3694 with talazoparib in patients with germline BRCA1/2 wild-type tumours demonstrated preliminary efficacy with ORR of 22% and clinical benefit rate of 35% among 51 evaluable patients, with thrombocytopenia reported as the most common adverse event [68].